


In the Claims:

Please withdraw claims 3-5, 7-8, 10, 15, 17, 19, 23, 30-32 and 35-44 without prejudice. Claims 1-2, 6, 9, 11-14, 16 and 18 remain pending in the application, as shown herein below.

1. (Original) A compound having the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein

R¹ and R² are independently selected from the group consisting of -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;


R³ is selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C₀-C₃.

2. (Original) A compound having the formula:

- 2 -

Attorney Docket No.: NRNZ-01048US1 DBB
DBB/NRNZ/1048US1/1048US1.103




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R^1 and R^2 are independently selected from the group consisting of $-OR'$, $-SR'$, $-NR'R'$, $-NO_2$, $-CN$, $-C(O)R'$, $-C(O)OR'$, $-C(O)NR'R'$, $-C(NR')NR'R'$, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of $-H$, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

R^3 is selected from the group consisting of $-H$, $-OR'$, $-SR'$, $-NR'R'$, $-NO_2$, $-CN$, $-C(O)R'$, $-C(O)OR'$, $-C(O)NR'R'$, $-C(NR')NR'R'$, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of $-H$, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C_0-C_3 .

3. (Withdrawn) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R^1 and R^2 are independently selected from the group consisting of $-H$, $-OR'$, $-SR'$, $-NR'R'$, $-NO_2$, $-CN$, $-C(O)R'$, $-C(O)OR'$, $-C(O)NR'R'$, $-C(NR')NR'R'$, trihalomethyl, halogen, alkyl,

substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C₀-C₄.

4. (Withdrawn) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R¹ and R² are independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C₀-C₄.

5. (Withdrawn) A compound having the formula:




or a pharmaceutically acceptable salt or hydrate thereof, wherein

R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C₀-C₄.

6. (Original) A compound having the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein


R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl and;

X is a linear alkyl or alkenyl chain of C₀-C₄.

7. (Withdrawn) A compound having the formula:

- 5 -


Attorney Docket No.: NRNZ-01048US1 DBB
DBB/NRNZ/1048US1/1048US1.103



or a pharmaceutically acceptable salt or hydrate thereof, wherein

R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl.

8. (Withdrawn) A compound having the formula:



or a pharmaceutically acceptable salt or hydrate thereof, wherein

R is independently selected from the group consisting of -H, -OR', -SR', -NR'R', -NO₂, -CN, -C(O)R', -C(O)OR', -C(O)NR'R', -C(NR')NR'R', trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R' is independently selected from the group consisting of -H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl.

9. (Previously presented) The compound of claim 1 where $R^1 = -\text{COOH}$ and $R^2 = -(\text{CH}_2)_2-\text{COOH}$.
10. (Withdrawn) The compound of claim 3 where $R^1 = -\text{CH}(\text{COOH})-(\text{CH}_2)_2-\text{COOH}$.
11. (Previously presented) The compound of claim 1 where $R^3 = \text{methyl}$ or Formula 3 where $R^2 = \text{methyl}$.
12. (Previously presented) The compound of claim 1 where $R^3 = \text{allyl}$ or Formula 3 where $R^2 = \text{allyl}$.
13. (Previously presented) The compound of claim 1 or Formula 3 where $X = -(\text{CH}_2)_3-$.
14. (Previously presented) The compound of claim 1 where $X = -(\text{CH}_2)_2-$.
15. (Withdrawn) The compound of claim 3 where $X = -(\text{CH}_2)_4-$.
16. (Previously presented) The compound of claim 1 where $X = -\text{CH}_2-\text{CH}=\text{CH}-$, (where the CH_2 of X is adjacent to the carbon attached to the NH_2 group).
17. (Withdrawn) The compound of claim 3 where $X = -\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$.
18. (Previously presented) The compound of claim 1 where $R^1 = -\text{COOH}$; $R^2 = -(\text{CH}_2)_2-\text{COOH}$; $R^3 = \text{H}$; $X = -(\text{CH}_2)_3-$.
19. (Withdrawn) The compound of claim 3 where $R^1 = -\text{CH}(\text{COOH})-(\text{CH}_2)_2-\text{COOH}$; $R^2 = \text{H}$; $X = -(\text{CH}_2)_4-$.

- 7 -

Attorney Docket No.: NRNZ-01048US1 DBB
DBB/NRNZ/1048US1/1048US1.103

20-22. (Cancel)

23. (Withdrawn) A method of treating a patient to protect neurons otherwise destined to degenerate or die as a result of an injury or disease, comprising administering to a patient an effective amount of one or more compounds of claim 1.

24-29. (Cancel)

30. (Withdrawn) The method of claim 23, wherein the disease is selected from the group consisting of Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, peripheral neuropathy, spinal muscular atrophy, Creutzfeldt-Jakob disease, AIDS dementia, progressive supranuclear palsy, myelinopathia centralis diffusa (vanishing white matter disease), chronic neurodegenerative disease, Down's syndrome, leukoencephalopathy and Schilder's disease.

31. (Withdrawn) The method of claim 23, wherein the injury or disease is a result of one or more conditions selected from the group consisting of neuroblastoma, head injury, traumatic brain injury, stroke, ischemic injury, hypoxic injury, reperfusion injury, epilepsy, cardiac artery bypass graft surgery, toxin damage, radiation damage and asphyxia.

32. (Withdrawn) The method of claim 23, wherein the injury or disease is a result of an inflammatory condition.

33-34. (Cancel)

35. (Withdrawn) A method of claim 23, wherein at least one other anti-apoptotic, anti-necrotic or neuroprotective agent is administered.

- 8 -

Attorney Docket No.: NRNZ-01048US1 DBB
DBB/NRNZ/1048US1/1048US1.103

36. (Withdrawn) The method of claim 23, further comprising administering another agent selected from the group consisting of insulin-like growth factor-I [IGF-I], insulin-like growth factor-II [IGF-II], transforming growth factor- β 1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding protein, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10 and FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 [BMP-2], glial-cell line derived neurotrophic factor, activity-dependant neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α - interferon, β - interferon, γ - interferon, consensus interferon, TNF- α , clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue [ORG 2766], dizolcipine [MK-801], selegiline, a glutamate antagonist, an AMPA antagonist and an anti-inflammatory agent.

37. (Withdrawn) The method of claim 36 wherein said glutamate antagonist is selected from the group consisting of NPS1506, GV1505260, MK-801 and GV150526.

38. (Withdrawn) The method of claim 36 wherein said AMPA antagonist is selected from the group consisting of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070 and LY300164.

39. (Withdrawn) The method of claim 36, wherein said anti-inflammatory agent is selected from the group consisting of an anti-MAdCAM-1 antibody and an antibody against an integrin α 4 β 1 receptor and an integrin α 4 β 7 receptor.

40. (Withdrawn) The method of claim 39 wherein said anti-MAdCAM-1 antibody is MECA-367.

- 9 -

Attorney Docket No.: NRNZ-01048US1 DBB
DBB/NRNZ/1048US1/1048US1.103

41. (Withdrawn) The method of claim 23 where the compound is (2S, 3'S, 8'R, 11'S) 2-
{[(3'-Amino-1'-aza -2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid
trifluoroacetate salt.
42. (Withdrawn) The method of claim 23 where the compound is (2S, 9'R, 12'S)-2-
{[(1',4'-Diaza-2'-oxobicyclo[7.3.0]dodecyl)-12'-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate.
43. (Withdrawn) The method of claim 23, wherein said condition is hypoxic ischemia.
44. (Withdrawn) The method of claim 23, wherein said condition is neurotoxicity.